Targeted Radiotherapy Remains Important in Pediatric Hodgkin Lymphoma With Slow Early Response to Chemotherapy
Researchers sought to assess the importance of radiotherapy in pediatric patients with early‐stage low-risk classical Hodgkin lymphoma.
Hodgkin Lymphoma
Response-Adapted Nivolumab Salvage Therapy Safe and Effective in Classical Hodgkin Lymphoma
Researchers sought to determine whether response-adapted sequential salvage therapy would be effective in patients with relapsed/refractory classical Hodgkin lymphoma.
Survival Advantage Seen for A+ADV in Advanced Hodgkin Lymphoma
Progression-free survival longer for brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine versus ABVD.
CVD Mortality Leading Cause of Death for Stage I, II Hodgkin Lymphoma
Among patients with cHL, mortality risk related to cancer has declined, but CVD mortality risk has decreased slowly or remained stable.
Radiotherapy May Confer Small Risk of Cardiovascular Disease in Early-Stage Hodgkin Lymphoma
The excess risk of cardiovascular disease from involved-field radiotherapy was 6.2%.
Treatment Impacts on Fertility for Patients With Hodgkin Lymphoma or Diffuse Large B-Cell Lymphoma
Researchers sought to determine the fertility-related issues and approaches for survivors of Hodgkin lymphoma and diffuse large B-cell lymphoma.
Tislelizumab Deemed an ‘Important Option’ for Relapsed/Refractory Classical Hodgkin Lymphoma
The median overall survival was not reached at 3 years.
Post-Traumatic Stress Symptoms Seen in Pediatric Hodgkin Lymphoma Survivors
Researchers sought to investigate the associations between PTSS and the experiences of pediatric survivors of Hodgkin lymphoma treated in the AHOD0031 study.
Serious Long-Term Adverse Events Decreased in Pediatric Hodgkin Lymphoma
A deepened understanding of long-term effects can help clinicians to better determine upfront therapy and monitoring strategies for pediatric patients with Hodgkin lymphoma.
Brentuximab Vedotin Shows Efficacy for Pediatric Patients With Classical Hodgkin Lymphoma
Researchers sought to determine the safety and efficacy of brentuximab vedotin in pediatric patients with classical Hodgkin lymphoma.
- Loading...
Loading...
Loading... 
Loading...